A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Novo Nordisk (NVO) lower Wednesday.

Roche’s once-daily pill, CT-996, delivered placebo-adjusted mean weight loss of 6.1% in a 澳洲幸运5官方开奖结果体彩网:Phase 1 trial of patients with obesity andᩚᩚᩚᩚᩚᩚ⁤⁤⁤⁤ᩚꦜ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ𒀱ᩚᩚᩚ without type 2 diabetes, the company said. 

Shares of Roche jumped more than 6% in Swiss trading as of 10:15 a.m. ET Wednesday. In the U.S., Zepbound maker Eli Lilly's stock fell more than 3% and Wegovy producer Novo Nordisk's shares dropped about 4% about 45 minutes after markets opened. 

Roche Added Drug To Pipeline Wi𒈔th Carmot Therapeutics Acquisition

Roche added CT-996 to its pipeline when it 澳洲幸运5官方开奖结果体彩网:agreed to acquire weight-loss drug developer Carmot Therapeutics last December. In May, Roche unveiled early stage data from another Carmot drug, CT-388, an injectable treatment for obesity and type 2 diabetes. 

Despite their signs of promise, Roche’s entries to the weight-loss drug market aren’t likely to be available for several years, 澳洲幸运5官方开奖结果体彩网:Chief Executive Officer (CEO) Teresa Graham previously told CNBC.